Slideshow
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
-
-
You can skip this ad in 3 seconds.
-
-
This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea.
Table of Contents
Slide 4: Dosage and Administration
Slide 17: Cautions, Effects, and Interactions
Slide 24: What to Tell Your Patient
Slide 29: Reference
